M-CSF 組換え体(リコンビナント)タンパク質 | Recombinant Human M-CSF

掲載日情報:2015/01/26 現在Webページ番号:111978

R&D Systems社製の高品質なM-CSFの組換え体タンパク質(Recombinant Human M-CSF)です。
本製品は研究用です。研究用以外には使用できません。

[在庫・価格 :2024年05月18日 00時00分現在]

※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
詳細 商品名
  • 商品コード
  • メーカー
  • 包装
  • 価格
  • 在庫
  • 法規制等
納期 文献数
M-CSF, Human, Recombinant
10日程度 ※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。 150
説明文
産生:E. coli,純度:>97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.,由来動物:Human,M.W.:18.5 kDa (monomer),Genbank:1435,エンドトキシンレベル:<1.0 EU per 1 µg of the protein by the LAL method.
別名:colony stimulating factor 1 (macrophage)
Genbank No: 1435
Protein Accession No: NP_757350
別包装品 別包装品あり
法規制等
保存条件 -20℃ 法規備考
掲載カタログ

製品記事 抗幹細胞マーカー抗体/抗造血幹細胞マーカー抗体(R&D Systems社)
関連記事
M-CSF, Human, Recombinant, Carrier-free
10日程度 ※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。 0
説明文
産生:E. coli,純度:>97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.,由来動物:Human,M.W.:18.5 kDa (monomer),Genbank:1435,エンドトキシンレベル:<1.0 EU per 1 µg of the protein by the LAL method.
別名:colony stimulating factor 1 (macrophage)
Genbank No: 1435
Protein Accession No: NP_757350
別包装品 別包装品あり
法規制等
保存条件 -20℃ 法規備考
掲載カタログ

製品記事 抗幹細胞マーカー抗体/抗造血幹細胞マーカー抗体(R&D Systems社)
関連記事

[在庫・価格 :2024年05月18日 00時00分現在]

※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。

M-CSF, Human, Recombinant

文献数: 150

説明文 産生:E. coli,純度:>97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.,由来動物:Human,M.W.:18.5 kDa (monomer),Genbank:1435,エンドトキシンレベル:<1.0 EU per 1 µg of the protein by the LAL method.
別名:colony stimulating factor 1 (macrophage)
Genbank No: 1435
Protein Accession No: NP_757350
別包装品 別包装品あり
法規制等
保存条件 -20℃ 法規備考
掲載カタログ

製品記事 抗幹細胞マーカー抗体/抗造血幹細胞マーカー抗体(R&D Systems社)
関連記事

M-CSF, Human, Recombinant, Carrier-free

文献数: 0

説明文 産生:E. coli,純度:>97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.,由来動物:Human,M.W.:18.5 kDa (monomer),Genbank:1435,エンドトキシンレベル:<1.0 EU per 1 µg of the protein by the LAL method.
別名:colony stimulating factor 1 (macrophage)
Genbank No: 1435
Protein Accession No: NP_757350
別包装品 別包装品あり
法規制等
保存条件 -20℃ 法規備考
掲載カタログ

製品記事 抗幹細胞マーカー抗体/抗造血幹細胞マーカー抗体(R&D Systems社)
関連記事

バルク注文に関して

バルク包装品も承ります。お気軽にお問合せ下さい。

目次に戻る

CF(Carrier-Free)とは?

R&D Systems社組換え体タンパク質製品では通常ウシ血清アルブミン(BSA)をキャリアタンパク質として加えています。キャリアタンパク質を加えることで組換え体タンパク質の安定性が高まり、使用期限が長くなります。また、より濃度の低い溶液での保管も可能となります。CF製品はBSAが含まれない製品となります。一般的に細胞培養や、ELISAのスタンダードにはBSA含有製品を推奨しています。CF製品はBSAが影響してしまうアプリケーションに推奨されます。

目次に戻る

Product Details

Source
E. coli-derived, Glu33-Ser190, with an N-terminal Met
Accession
NP_757350
Structure
Disulfide-linked homodimer
Purity
>97%, by SDS-PAGE with silver staining, under reducing conditions.
Predicted Molecular Mass
18.5 kDa (monomer)
SDS-PAGE
37 kDa, non-reducing conditions
Activity
Measured in a cell proliferation assay using M‑NFS‑60 mouse myelogenous leukemia lymphoblast cells. Nakoinz, I. et al. (1990) J. Immunol. 145

目次に戻る

Additional Information

Molecule Information
M-CSF
Aliases
CSF1; CSF-1
Entrez Gene IDs
1435 (Human); 12977 (Mouse)
Background
M-CSF/CSF-1
M-CSF, also known as CSF-1, is a four-alpha-helical-bundle cytokine that is the primary regulator of macrophage survival, proliferation and differentiation. M-CSF is also essential for the survival and proliferation of osteoclast progenitors. M-CSF also primes and enhances macrophage killing of tumor cells and microorganisms, regulates the release of cytokines and other inflammatory modulators from macrophages, and stimulates pinocytosis. M-CSF increases during pregnancy to support implantation and growth of the decidua and placenta. Sources of M-CSF include fibroblasts, activated macrophages, endometrial secretory epithelium, bone marrow stromal cells and activated endothelial cells. The M-CSF receptor (c-fms) transduces its pleotropic effects and mediates its endocytosis. M-CSF mRNAs of various sizes occur. Full length human M-CSF transcripts encode a 522 amino acid (aa) type I transmembrane (TM) protein with a 464 aa extracellular region, a 21 aa TM domain, and a 37 aa cytoplasmic tail that forms a 140 kDa covalent dimer. Differential processing produces two proteolytically cleaved, secreted dimers. One is an N- and O- glycosylated 86 kDa dimer, while the other is modified by both glycosylation and chondroitin-sulfate proteoglycan (PG) to generate a 200 kDa subunit. Although PG-modified M-CSF can circulate, it may be immobilized by attachment to type V collagen. Shorter transcripts encode M-CSF that lack cleavage and PG sites and produce an N-glycosylated 68 kDa TM dimer and a slowly produced 44 kDa secreted dimer. Although forms may vary in activity and half-life, all contain the N-terminal 150 aa portion that is necessary and sufficient for interaction with the M-CSF receptor. The first 223 aa of mature human M-CSF shares 88%, 86%, 81% and 74% aa identity with corresponding regions of dog, cow, mouse and rat M-CSF, respectively. Human M-CSF is active in the mouse, but mouse M-CSF is reported to be species-specific.

目次に戻る

Citations

Citations of cell biology reagents in peer reviewed literature can be used as a direct measure of product quality. They can also provide crucial insightinto their use under specialized or unique experimental conditions. Because of the importance published citations have to researchers, R&D Systems personnelmanually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but alsoprovides information about sample types, species, and experimental conditions.

CLEC5A is critical for dengue virus-induced inflammasome activation in human macrophages.
Chen N, Chen S, Hsieh S, Li L, Lin W, Lin Y, Tsai I, Wu M, Yang A
Blood 2013 121:95-106
Species: Human
Protein Application: Media Supplement - Cell Prep


Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression.
Du J, He J, Hong B, Hou J, Kwak L, Li H, Lin P, Liu H, Liu Z, Lu Y, Qian J, Xu J, Yang J, Yi Q, Zhang M, Zheng Y, Zhong Y
PLoS ONE 2013 8:e82453
Species: Human
Protein Application: Bioassay


Functional consequences of the macrophage stimulating protein 689C inflammatory bowel disease risk allele.
Chaudhuri , Amitabha, Diehl , Lauri, Egen , Jackson , Faubion , William , Gonzalez , Lino C, Graham , Robert R, Kauder , Steven E, Keir , Mary E, Lazarus , Robert A, Luis , Elizabet, Lutman , Jeff, Mai , Elaine, Maun , Henry R, N'Diaye , Elsa N, Ratti , Navneet, Sa , Susan M, Santell , Lydia, Stefanich , Eric, Wright , Lilyan Y, Young , Judy
PLoS ONE 2013 8:e83958
Species: Human
Protein Application: cell culture


Macrophages induce differentiation of plasma cells through CXCL10/IP-10.
J. Exp. Med. 2012 209:1813-23
Species: Human
Protein Application: Bioassay


HIV-1 reduces Abeta-degrading enzymatic activities in primary human mononuclear phagocytes.
Ikezu T, Kiyota T, Lan X, Peng H, Xu J, Zheng JC
J. Immunol. 2011 186:6925-32
Species: Human
Protein Application: Bioassay


Protein kinase C and NF-kappaB-dependent CD4 downregulation in macrophages induced by T cell-derived soluble factors: consequences for HIV-1 infection.
Cowley SA, James W, Raposo RA, Thomas B, Trudgian DC, van Wilgenburg B
J. Immunol. 2011 187:748-59
Species: Human
Protein Application: Bioassay


Characterisation of the osteoclastogenic potential of human osteoblastic and fibroblastic conditioned media.
Costa-Rodrigues J, Fernandes MH, Sampaio P, Teixeira CA
J. Cell. Biochem. 2010 109:205-16
Species: Human
Protein Application: Bioassay


Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma.
Anagnostopoulos I, Barlow R, Bonifer C, Bouhlel MA, Callen DF, Cockerill PN, Dorken B, Giefing M, Harte MF, Hummel M, Janz M, Johrens K, Kochert K, Kreher S, Kumar R, Lamprecht B, Lenze D, Mathas S, Richter J, Siebert R, Soler E, Stadhouders R, Stein H, Walter K, Wurster KD
Nat. Med. 2010 16:571-9
Species: Human
Protein Application: Bioassay


IL-3 inhibits human osteoclastogenesis and bone resorption through downregulation of c-Fms and diverts the cells to dendritic cell lineage.
Barhanpurkar AP, Gupta N, Tomar GB
J. Immunol. 2010 185:2261-72
Species: Human
Protein Application: Bioassay


Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle.
Delaisse JM, Soe K
J. Bone Miner. Res. 2010 25:2184-92
Species: Human
Protein Application: Bioassay


目次に戻る

お問い合わせ先

(テクニカルサポート 試薬担当)

reagent@funakoshi.co.jp

製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。